Gut Microbiota and Complications of Liver Disease.
Gut Microbiota and Complications of Liver Disease.
复制标题
DOI：
10.1016/j.gtc.2016.09.013
复制
发表时间：
2017-03
影响因子：
3.7
通讯作者：
Bajaj JS
中科院分区：
文献类型：
--
作者：
Acharya C;Bajaj JS
慢性肝病的流行以及如何对抗其并发症多年来一直是一个具有挑战性的方面。新的实验室技术使人类肠道微生物组的分析更容易，也更详细。随着对生态失调以及这种生态失调如何影响肝脏疾病的深入了解，科学家们在肠道和肝脏中有了新的目标。在NASH和酒精性肝硬化中，菌群失调与内毒素血症相关，并会加重肝损伤。微生物群的组成随着肝硬化和失代偿的发展而变化。除了微生物外，胆汁酸在这一竞技场中的作用也正在被发现，FXR受体激动剂等新的治疗方法正在出现。改变的肠道微生物群在肝硬化及其调节中起着重要作用，以防止疾病进展变化，同时必须调节或增强胆汁酸生理学以帮助预防肝硬化及其并发症。
The epidemic of chronic liver disease and how to combat its complications has been a challenging aspect for many years. New laboratory techniques have made analysis of the human intestinal microbiome easier and also more detailed. With insight into dysbiosis and how this dysbiosis impacts liver disease, scientists have new targets in the intestine and liver. Dysbiosis is associated with endotoxemia and propagates liver injury in NASH and alcoholic cirrhosis. The composition of the microbiota changes with the development of cirrhosis and decompensation Apart from microbes, the role that bile acids play in this arena are also being discovered and newer treatments like FXR receptor agonists are coming into the picture. Altered gut microbiota plays an important role in cirrhosis and its modulation to prevent disease progression changes, and concomitantly bile acid physiology must be regulated or augmented to help prevent cirrhosis and its complications.